---
title: "Sacubitril/valsartan after AFib ablation tied to lower recurrence vs valsartan alone"
id: "aha-news-1-blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after"
canonical_url: "https://medichelpline.com/clinical-feed/aha-news-1-blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "AHA News (American Heart Association)"
source_url: "https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation"
published_at: "2026-11-08T22:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sacubitril/valsartan after AFib ablation tied to lower recurrence vs valsartan alone
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/aha-news-1-blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** AHA News (American Heart Association)
- **Source URL:** [Original Journal Publication](https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation)
- **Published At:** 2026-11-08T22:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A randomized controlled trial in China enrolled 320 adults with both **atrial fibrillation (AFib)** and **hypertension** who underwent catheter ablation and were followed for 12 months. - Investigators randomly assigned 161 participants to **sacubitril/valsartan** (100 mg once daily) and 159 to **valsartan** (80 mg once daily) after ablation. - The trial team observed a lower documented recurrence of atrial tachyarrhythmias in the combination group at 12 months: 18% versus 28.3% in the valsartan-alone group. - Clinic systolic blood pressure fell by about 10 mm Hg in both treatment arms; 24-hour ambulatory blood pressure reductions were similar between groups, suggesting blood pressure change alone may not explain the rhythm outcome. - Heart rhythm monitoring combined handheld single-lead home ECGs with scheduled 12-lead ECGs and 24-hour Holter at 1, 3, 6 and 12 months; monitoring was intermittent rather than continuous. - The trial was open-label; however, ECG-documented events were adjudicated centrally by a blinded independent committee. - Participants averaged 68 years of age; 41.2% were women; 66.6% had paroxysmal AFib. - The study ran across three hospitals in China between February 2023 and January 2025. - Investigators reported that the study’s findings are preliminary (abstract presented at Scientific Sessions 2026) and not yet peer-reviewed or published as a full manuscript. - Limitations include open-label design, intermittent rhythm monitoring that may miss brief or asymptomatic AFib episodes, and limited generalizability outside older adults with hypertension in China.
## Clinical Analysis & Structured Key Points
[Skip Navigation](https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation#site_content) [Skip to main content](https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation#site_content) * [ Warning Signs ](https://www.heart.org/en/about-us/heart-attack-and-stroke-symptoms) * [ Volunteer ](http://www.heart.org/HEARTORG/volunteer/volunteerForm.jsp) * [ Donate ](https://www2.heart.org/site/SPageNavigator/donatenow_heart.html?s_src=mobile) [ ![return to American Heart Association ](https://www.heart.org/-/media/images/logos/global-do-no-edit/header/aha_icon.svg?h=100&w=200&hash=3022F7F39B2275C85A344A476BED5540263C280C) ](https://www.heart.org/en) [ Newsroom ](https://newsroom.heart.org/) * [![](https://www.heart.org/-/media/feature/navigation/topnav/icon_symptoms.svg?h=19&w=19&hash=A63C8FC4FDBFCB523AA30B93358748A9E553BADE) Heart Attack And Stroke Symptoms ](https://www.heart.org/en/about-us/heart-attack-and-stroke-symptoms) * [![](https://www.heart.org/-/media/feature/navigation/topnav/icon_volunteer.svg?h=24&w=24&hash=D803FE311C9E2131B12D1CAB8DE3EC116DBF43E9) Volunteer ](https://www.heart.org/HEARTORG/volunteer/volunteerForm.jsp) * [![](https://www.heart.org/-/media/feature/navigation/topnav/donateheartwhite.svg?h=20&w=22&hash=20AE6294C88817CD59AF2B5B4013D6446B60E6F1) Donate ](https://www2.heart.org/site/SPageNavigator/donatenow_heart.html?s_src=nav&pagename=%2Fdonatenow_heart&utm_expid=.Gd9MG4GFQjaAcfhuC0-%20%20l4w.0&utm_referrer=https%3A%2F%2Fwww.heart.org%2F) * ![](https://www.heart.org/-/media/project/common/glyphs/search.svg?h=24&w=24&hash=48F9050F2DB090F226BF5F840DE12DC3B8082466)Search × Search Menu [ Newsroom ](https://newsroom.heart.org/) * News Media Access * [News Media Embargoed Access](https://newsroom.heart.org/access/apply) * [Login to Password Protected Newsroom](https://newsroom.heart.org/access/embargoed-news) * [Apply for Embargoed Access](https://newsroom.heart.org/access/apply) * Policies & Resources * [Embargo Policy and Guidelines](https://newsroom.heart.org/policies/embargo-policy) * [American Heart Association Fact Sheets](https://newsroom.heart.org/policies/american-heart-association-fact-sheets) * [American Heart Association News Stories](https://www.heart.org/en/news) * [Boilerplates](https://newsroom.heart.org/policies/boilerplates) * [Copyright Permissions](https://www.heart.org/en/about-us/statements-and-policies/copyright-permission-guidelines) * [Glossary of Scientific Terms](https://newsroom.heart.org/policies/glossary-of-scientific-terms) * [Linking Policy](https://www.heart.org/en/about-us/statements-and-policies/linking-policy) * [Scientific Statements/Guidelines](https://professional.heart.org/professional/GuidelinesStatements/UCM_316885_Guidelines-Statements.jsp) * [Scientific Publications: Purposes-Processes](https://professional.heart.org/professional/GuidelinesStatements/PublicationDevelopment/UCM_475318_Publication-Development.jsp) * [Statistics](https://www.heart.org/en/about-us/heart-and-stroke-association-statistics?uid=1740) * Multimedia Resources * [Multimedia Resources](https://newsroom.heart.org/multimedia) * [Animation/Video](https://newsroom.heart.org/multimedia/animation-video) * [Images/Graphics](https://newsroom.heart.org/multimedia/images-graphics) * [Audio](https://newsroom.heart.org/multimedia/audio) * [Usage Policy](https://newsroom.heart.org/multimedia/usage) * Connect With Us * [Connect With Us](https://newsroom.heart.org/connect/contacts) * [Media Contacts](https://newsroom.heart.org/connect/contacts) * [Consumer/Media Connections](https://newsroom.heart.org/connect/consumer-media-connections) ![Submit Search](https://www.heart.org/-/media/project/common/glyphs/search.svg) * [ Twitter ](https://twitter.com/HeartNews) * [ Facebook ](https://www.facebook.com/AmericanHeart/timeline) * [ YouTube ](http://www.youtube.com/americanheartassoc) * [ RSS ](https://newsroom.heart.org/rss) * [ Email Alerts ](https://newsroom.heart.org/alerts) 1. [Newsroom](https://newsroom.heart.org/) 2. [Search News Releases](https://newsroom.heart.org/news) 3. Blood pressure medication combo linked to fewer irregular heart rhythms after ablation **Categories:** [Scientific Conferences & Meetings](https://newsroom.heart.org/news?c=858), [Heart News](https://newsroom.heart.org/news?c=856) | Published: November 08, 2026 # Blood pressure medication combo linked to fewer irregular heart rhythms after ablation American Heart Association Scientific Sessions 2026, Late-Breaking Science Abstract 23117 [ ![facebook](https://newsroom.heart.org/media/themes/5cf02be72cfac21af0e27a3f/fonts/facebook.svg) Facebook ](http://www.facebook.com/sharer.php?u=https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation) [ ![twitter](https://newsroom.heart.org/media/themes/5cf02be72cfac21af0e27a3f/fonts/twitter.svg) Twitter ](http://twitter.com/share?text=Blood%20pressure%20medication%20combo%20linked%20to%20fewer%20irregular%20heart%20rhythms%20after%20ablation&url=https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation) [ ![facebook](https://newsroom.heart.org/media/themes/5cf02be72cfac21af0e27a3f/fonts/linkedin.svg) LinkedIn ](https://www.linkedin.com/shareArticle?mini=true&url=https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation) ![facebook](https://newsroom.heart.org/media/themes/5cf02be72cfac21af0e27a3f/fonts/envelope-fill.svg) Email [ ![facebook](https://newsroom.heart.org/media/themes/5cf02be72cfac21af0e27a3f/fonts/printer-fill.svg) Print ](https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation?print=1) **Research Highlights:** * In a randomized clinical trial of more than 300 adults, ages 55 years and older in China with high blood pressure who had an ablation procedure for atrial fibrillation, treatment with a combination of sacubitril and valsartan was associated with fewer recurring irregular heart rhythms than treatment with valsartan alone, after a 12-month follow-up period. * Blood pressure decreased by similar amounts in both groups, suggesting the difference in recurring abnormal heart rhythms may not be explained by blood pressure reduction alone. * _Note: The study featured in this news release is a research abstract.__Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal._ **Embargoed until 4:00 p.m. CT/5:00 p.m. ET, Sunday, November 8, 2026** **_This news release contains updated information provided by the researchers and not listed in the abstract._** CHICAGO, Nov. 8, 2026 — Among older adults with [high blood pressure](https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure) and [atrial fibrillation](https://www.heart.org/en/health-topics/atrial-fibrillation/what-is-atrial-fibrillation-afib-or-af), treatment with a combination of two blood pressure medications was associated with fewer recurring irregular heart rhythms after an ablation procedure compared with only one of the medications alone, according to new, independent, preliminary, late-breaking science presented today at the American Heart Association’s **Scientific Sessions 2026**. The meeting on Nov. 6-9 in Chicago is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. According to the American Heart Association atrial fibrillation, also called AFib, is an irregular heart rhythm that can cause symptoms such as a fast, fluttering or pounding heartbeat, shortness of breath, tiredness or weakness, and/or chest pain or difficulty exercising. AFib ablation is a procedure that uses heat or cold to treat small areas of heart tissue that are causing the abnormal electrical signals, helping the heart maintain a more normal rhythm. Although ablation treats the abnormal electrical activity responsible for AFib, it may not reverse underlying structural changes in the heart that may contribute to AFib. Over time, high blood pressure can place additional stress on the heart and contribute to enlargement, increased pressure and scarring of the heart muscle, and also narrowing of the arteries. These physical changes to the heart create an environment in which AFib can develop again even after an initially successful ablation. “For many patients, AFib recurrence after an ablation can mean the return of symptoms, additional monitoring, medications or treatments to help restore a normal heart rhythm, and sometimes another ablation procedure,” said the study’s lead author Wei Zhang, M.D., Ph.D., a cardiologist in the department of cardiovascular medicine at the Shanghai Institute of Hypertension at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine in Shanghai, China. “Our goal was to find out whether treatment with a single or combination of blood pressure medications after ablation could affect the chance of AFib returning.” **What are the study’s key findings?** * At 12 months after an AFib ablation procedure, the sacubitril/valsartan combination was associated with a lower rate of documented recurrence of AFib or related atrial arrhythmias compared with patients in the valsartan-alone group. * Documented atrial tachyarrhythmias (abnormally fast heart rhythms that begin in the heart’s upper chambers) recurrence occurred in 18% of participants in the sacubitril/valsartan group compared to 28.3% in the valsartan group. * Systolic blood pressure measured at clinic visits fell by about 10 mm Hg in both groups, and there was no significant difference in the reduction in 24-hour ambulatory blood pressure between the two treatment groups. “Our findings reinforce the idea that treating AFib does not end with the ablation procedure, and managing hypertension remains an important part of comprehensive AFib care. What was particularly interesting to us was that the difference in AFib recurrence was observed even though blood pressure reductions were similar between the two groups. This raises the possibility that after AFib ablation, the type of treatment used to lower blood pressure may be as important as how much blood pressure is lowered,” said Zhang. He added that the study findings should not be interpreted as suggesting that ablation alone or medication alone is sufficient to prevent AFib from recurring. “AFib is a complex condition, and successful long-term management requires both effective rhythm treatment and careful management of underlying cardiovascular risk factors, particularly hypertension,” Zhang said. **What are the study’s details, background, design and limitations?** * The randomized, controlled trial included 320 patients with both AFib and hypertension (clinic blood pressure >130/80 mm Hg) who received catheter ablation at three hospitals in China between February 2023 and January 2025. * Participants were an average age of 68 years old; 41.2% were women; and 66.6% had paroxysmal AFib (irregular heart rhythm that occurs in episodes and returns to a normal rhythm). * After the ablation procedure, 161 patients were randomly assigned to start sacubitril/valsartan (100 mg once daily), and 159 patients were randomly assigned to start valsartan (80 mg once daily). Since all the participants had high blood pressure and required treatment, researchers used valsartan, an active blood pressure medication, as the comparison instead of a placebo. Valsartan blocks the angiotensin II type 1 receptor, while sacubitril is converted to an active metabolite that inhibits neprilysin, an enzyme that breaks down natriuretic peptides. * Researchers monitored the participants for 12 months after their ablation procedure, with scheduled visits at 1, 3, 6 and 12 months, to determine whether they had a documented recurrence of AFib or related abnormal heart rhythms. During follow-up, heart rhythm was assessed using handheld single-lead ECG devices for home monitoring, as well as standard 12-lead ECG and 24-hour Holter monitoring at scheduled visits. * The study had several limitations. It was an open-label trial, meaning that patients and treating physicians knew which medication group they had been assigned to; however, ECG-documented recurrence events were centrally adjudicated by an independent team blinded to information about which patients received which treatment. Heart rhythm monitoring was intermittent rather than continuous, so some brief or symptom-free AFib episodes may have been missed. In addition, the study focused on older adults with hypertension undergoing AFib ablation in China, so the findings may not necessarily apply to younger adults, people without hypertension or people living in other countries. Co-authors and disclosures are listed in the abstract. The study was supported by research grants from the National Natural Science Foundation of China, the Ministry of Science and Technology of China, Shanghai municipal research programs and the Clinical Research Program of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The funders had no role in the study design; collection, analysis or interpretation of the data; preparation or review of the manuscript; or the decision to submit the results for publication. Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available [here](https://www.heart.org/en/about-us/aha-financial-information). **Additional Resources:** * Multimedia is available on the right column of the release [link](https://newsroom.heart.org/news/blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after-ablation?preview=006de4e02a8d39b154d4834e3443b3e4) * View the [abstract](https://eppro01.ativ.me/appinfo.php?page=Session&project=AHA26&id=P16211&server=eppro01.ativ.me) in the American Heart Association Scientific Sessions 2026 [Online Program Planner](https://eppro01.ativ.me/web/planner.php?id=AHA26) * American Heart Association news release: [Ablation reduces stroke risk for AFib and may remove need for some types of blood thinners](https://newsroom.heart.org/news/ablation-reduces-stroke-risk-for-afib-and-may-remove-need-for-some-types-of-blood-thinners) (Nov. 2025) * American Heart Association/American College of Cardiology Guideline news release: [Early Rhythm Control, Lifestyle Modification and More Tailored Stroke Risk Assessment Are Top Goals in Managing Atrial Fibrillation](https://newsroom.heart.org/news/early-rhythm-control-lifestyle-modification-and-more-tailored-stroke-risk-assessment-are-top-goals-in-managing-atrial-fibrillation) (Nov. 2023) * American Heart Association health information: [Diagnosis and Treatment of Atrial Fibrillation](https://www.heart.org/en/health-topics/atrial-fibrillation/treatment-and-prevention-of-atrial-fibrillation) * About [Scientific Sessions 2026](https://professional.heart.org/en/meetings/scientific-sessions) * For more news at the American Heart Association’s Scientific Sessions 2026, follow us on X [@HeartNews](https://x.com/HeartNews), #ScientificSessions26 **###** **About the American Heart Association** The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on [heart.org](http://www.heart.org/en), [Facebook](http://facebook.com/AmericanHeart), [X](http://x.com/American_Heart) or by calling 1-800-AHA-USA1. **For Media Inquiries and American Heart Association Expert Perspective:** American Heart Association Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org Amanda Ebert: Amanda.Ebert@heart.org For Public Inquiries: 1-800-AHA-USA1 (242-8721) [heart.org](https://www.heart.org/en) and [stroke.org](https://www.stroke.org/en) ## Related Images Previous Slide Next Slide [ ![](https://iprsoftwaremedia.com/67/files/20259/58e16709a138353201a85a4e_Blood%20Pressure%20Medication/Blood%20Pressure%20Medication_ce769455-d4e6-442e-988c-c956c0dcbd32-prv.jpg?v=ce769455-d4e6-442e-988c-c956c0dcbd32) ](https://newsroom.heart.org/_gallery/get_file/?file_id=58e16709a138353201a85a4e&file_ext=.jpg&page_id=6aeb7a1c3d6332302906c092&download=true) ### Blood Pressure Medication copyright American Heart Association [Download (339.8 kB)](https://newsroom.heart.org/_gallery/get_file/?file_id=58e16709a138353201a85a4e&file_ext=.jpg&page_id=6aeb7a1c3d6332302906c092&download=true "Blood Pressure Medication") ![Blood Pressure Medication](https://iprsoftwaremedia.com/67/files/20259/58e16709a138353201a85a4e_Blood%20Pressure%20Medication/Blood%20Pressure%20Medication_ce769455-d4e6-442e-988c-c956c0dcbd32-prv.jpg?v=ce769455-d4e6-442e-988c-c956c0dcbd32) # Blood Pressure Medication copyright American Heart Association Please see [AHA/ASA Multimedia Materials Usage Policy](https://newsroom.heart.org/multimedia/usage). I have read the AHA/ASA Multimedia Materials Usage Policy and agree to the terms of use [ Download (339.8 kB) ](https://newsroom.heart.org/_gallery/get_file/?file_id=58e16709a138353201a85a4e&file_ext=.jpg&page_id=6aeb7a1c3d6332302906c092) [File Permalink](https://newsroom.heart.org/file?fid=58e16709a138353201a85a4e) [ ![](https://iprsoftwaremedia.com/67/files/202610/6093775c4eabd9f3be07499e406962e7/6aeb94ae3d6332a1ad06c0fa_Wei%20Zhang%20M.D.%20Ph.D./Wei%20Zhang%20M.D.%20Ph.D._5d39b596-376e-42df-9aa1-b13fe848e89f-prv.jpg?v=5d39b596-376e-42df-9aa1-b13fe848e89f) ](https://newsroom.heart.org/_gallery/get_file/?file_id=6aeb94ae3d6332a1ad06c0fa&file_ext=.jpg&page_id=6aeb7a1c3d6332302906c092&download=true) ### Wei Zhang, M.D., Ph.D. Wei Zhang, M.D., Ph.D., a cardiologist in the department of cardiovascular medicine at the Shanghai Institute of Hypertension at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine in Shanghai, China copyright Ruijin H
## Related Clinical Research

- [Switching to ARNI Associated with Lower Short-Term New-Onset Atrial Fibrillation in HFrEF](https://medichelpline.com/clinical-feed/pubmed-42740677.md) (DOI: 10.1093/ehjcvp/pvag074)
- [GLP-1 drugs tied to lower diabetes progression and cardiovascular events than metformin](https://medichelpline.com/clinical-feed/aha-news-4-glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [Rising stroke incidence in adults under 55 despite overall declines in the US](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rates-are-falling-overall-but-rising-among-adults-under-55.md)
- [Impact of Nighttime Light Exposure on Heart Health and Disease Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-nighttime-light-exposure-may-alter-the-heart-and-increase-disease-risk.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.